MEDP250117P270000
- 2.23
- 0.000.00%
Medpace Newsroom
TD Cowen Maintains Medpace(MEDP.US) With Buy Rating, Cuts Target Price to $370
Could The Market Be Wrong About Medpace Holdings, Inc. (NASDAQ:MEDP) Given Its Attractive Financial Prospects?
Why Medpace (MEDP) Outpaced the Stock Market Today
Lower Than Expected Results Dragged Medpace Holdings (MEDP) in Q3
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025
CRO Services Market Report 2024, With Key Player Profiles for Medpace, ICON, IQVIA, Syneos Health, Parexel, Charles River Laboratories, Thermofisher Scientific, Pharmaron Beijing and Altasciences
Truist Financial Maintains Medpace(MEDP.US) With Hold Rating
Truist Financial Issues a Hold Rating on Medpace Holdings (MEDP)
PACS Vs. MEDP: Which Stock Is the Better Value Option?
10 Health Care Stocks Whale Activity In Today's Session
Is It Time To Consider Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Medpace Holdings Is Maintained at Neutral by Baird
Medpace Hldgs Analyst Ratings
Baird Maintains Medpace(MEDP.US) With Hold Rating, Raises Target Price to $354
Express News | Medpace Holdings Inc : Baird Raises Target Price to $354 From $349
Insiders At Medpace Holdings Sold US$525m In Stock, Alluding To Potential Weakness
Medpace Holdings (MEDP) Reveals "Shocking" Bookings Miss, Shares Fall - Hagens Berman
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Medpace Holdings, Inc. for Potential Violations of Securities Laws
Medpace Holdings, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Truist Financial Maintains Medpace(MEDP.US) With Hold Rating, Announces Target Price $347